Fridkis-Hareli M - Search Results

1

Peptide-based immunotherapeutics and vaccines.

Reche PA, Fernandez-Caldas E, Flower DR, Fridkis-Hareli M, Hoshino Y. Reche PA, et al. Among authors: fridkis hareli m. J Immunol Res. 2014;2014:256784. doi: 10.1155/2014/256784. Epub 2014 Feb 4. J Immunol Res. 2014. PMID: 24741581 Free PMC article. No abstract available.

2

Peptide-Based Immunotherapeutics and Vaccines 2017.

Reche P, Flower DR, Fridkis-Hareli M, Hoshino Y. Reche P, et al. Among authors: fridkis hareli m. J Immunol Res. 2018 Jul 15;2018:4568239. doi: 10.1155/2018/4568239. eCollection 2018. J Immunol Res. 2018. PMID: 30116752 Free PMC article. No abstract available.

3

Peptide-Based Immunotherapeutics and Vaccines 2015.

Reche P, Flower DR, Fridkis-Hareli M, Hoshino Y. Reche P, et al. Among authors: fridkis hareli m. J Immunol Res. 2015;2015:349049. doi: 10.1155/2015/349049. Epub 2015 Dec 20. J Immunol Res. 2015. PMID: 26798661 Free PMC article. No abstract available.

4

Peptide variants of viral CTL epitopes mediate positive selection and emigration of Ag-specific thymocytes in vivo.

Fridkis-Hareli M, Reche PA, Reinherz EL. Fridkis-Hareli M, et al. J Immunol. 2004 Jul 15;173(2):1140-50. doi: 10.4049/jimmunol.173.2.1140. J Immunol. 2004. PMID: 15240703 Free article.

5

Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Fridkis-Hareli M. Fridkis-Hareli M. Clin Dev Immunol. 2013;2013:826191. doi: 10.1155/2013/826191. Epub 2013 Nov 13. Clin Dev Immunol. 2013. PMID: 24324511 Free PMC article. Review.

6

Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

Stern JN, Illés Z, Reddy J, Keskin DB, Fridkis-Hareli M, Kuchroo VK, Strominger JL. Stern JN, et al. Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1620-5. doi: 10.1073/pnas.0409022102. Epub 2005 Jan 21. Proc Natl Acad Sci U S A. 2005. PMID: 15665083 Free PMC article.

7

Binding of random copolymers of three amino acids to class II MHC molecules.

Fridkis-Hareli M, Aharoni R, Teitelbaum D, Arnon R, Sela M, Strominger JL. Fridkis-Hareli M, et al. Int Immunol. 1999 May;11(5):635-41. doi: 10.1093/intimm/11.5.635. Int Immunol. 1999. PMID: 10330269

8

Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

Fridkis-Hareli M, Stern JN, Fugger L, Strominger JL. Fridkis-Hareli M, et al. Hum Immunol. 2001 Aug;62(8):753-63. doi: 10.1016/s0198-8859(01)00279-8. Hum Immunol. 2001. PMID: 11476898

9

New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination.

Fridkis-Hareli M, Reinherz EL. Fridkis-Hareli M, et al. Med Immunol. 2004 Dec 8;3(1):2. doi: 10.1186/1476-9433-3-2. Med Immunol. 2004. PMID: 15588284 Free PMC article.

10

Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.

Fridkis-Hareli M, Neveu JM, Robinson RA, Lane WS, Gauthier L, Wucherpfennig KW, Sela M, Strominger JL. Fridkis-Hareli M, et al. J Immunol. 1999 Apr 15;162(8):4697-704. J Immunol. 1999. PMID: 10202010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters